Advertisement
Screener

AMARIN CORP PLC\UK (AMRN) Increase (Decrease) in Contract with Customer, Liability

2.8 / 5 stars · 68/120 Roast Me

AMARIN CORP PLC\UK Increase (Decrease) in Contract with Customer, Liability

AMARIN CORP PLC\UK (AMRN) reported Increase (Decrease) in Contract with Customer, Liability of -$4.85 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-02.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-03-02

  • AMARIN CORP PLC\UK increase (decrease) in contract with customer, liability for the quarter ending 2024-12-31 was $0.00.
  • AMARIN CORP PLC\UK increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was $0.00.
  • AMARIN CORP PLC\UK increase (decrease) in contract with customer, liability for the quarter ending 2024-06-30 was -$4.45M.
  • AMARIN CORP PLC\UK increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was -$401.00K.
  • AMARIN CORP PLC\UK increase (decrease) in contract with customer, liability for fiscal 2024 was -$4.85M.
  • AMARIN CORP PLC\UK increase (decrease) in contract with customer, liability for fiscal 2023 was -$10.50M.
  • AMARIN CORP PLC\UK increase (decrease) in contract with customer, liability for fiscal 2022 was -$1.36M.
  • AMARIN CORP PLC\UK increase (decrease) in contract with customer, liability for fiscal 2021 was -$1.92M.
Period endIncrease (Decrease) in Contract with Customer, Liability 3 monthIncrease (Decrease) in Contract with Customer, Liability 6 monthIncrease (Decrease) in Contract with Customer, Liability 9 monthIncrease (Decrease) in Contract with Customer, Liability 12 month
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$0.00
derived: sum of 2 quarters · filed 2026-03-02
-$4.45M
derived: sum of 3 quarters · filed 2026-03-02
-$4.85M
10-K · filed 2026-03-02
2024-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29
-$4.45M
derived: sum of 2 quarters · filed 2025-10-29
-$4.85M
10-Q · filed 2025-10-29
-$4.97M
derived: sum of 4 quarters · filed 2026-03-02
2024-06-30-$4.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30
-$4.85M
10-Q · filed 2025-07-30
-$4.97M
derived: sum of 3 quarters · filed 2026-03-02
-$5.36M
derived: sum of 4 quarters · filed 2026-03-02
2024-03-31-$401.00K
10-Q · filed 2025-05-07
-$525.00K
derived: sum of 2 quarters · filed 2026-03-02
-$907.00K
derived: sum of 3 quarters · filed 2026-03-02
-$10.45M
derived: sum of 4 quarters · filed 2026-03-02
2023-12-31-$124.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
-$506.00K
derived: sum of 2 quarters · filed 2026-03-02
-$10.05M
derived: sum of 3 quarters · filed 2026-03-02
-$10.50M
10-K · filed 2026-03-02
2023-09-30-$382.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30
-$9.93M
derived: sum of 2 quarters · filed 2024-10-30
-$10.37M
10-Q · filed 2024-10-30
-$10.72M
derived: sum of 4 quarters · filed 2025-03-12
2023-06-30-$9.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31
-$9.99M
10-Q · filed 2024-07-31
-$10.34M
derived: sum of 3 quarters · filed 2025-03-12
-$10.65M
derived: sum of 4 quarters · filed 2025-03-12
2023-03-31-$445.00K
10-Q · filed 2024-05-01
-$796.00K
derived: sum of 2 quarters · filed 2025-03-12
-$1.11M
derived: sum of 3 quarters · filed 2025-03-12
-$1.44M
derived: sum of 4 quarters · filed 2025-03-12
2022-12-31-$351.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12
-$662.00K
derived: sum of 2 quarters · filed 2025-03-12
-$991.00K
derived: sum of 3 quarters · filed 2025-03-12
-$1.36M
10-K · filed 2025-03-12
2022-09-30-$311.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01
-$640.00K
derived: sum of 2 quarters · filed 2023-11-01
-$1.01M
10-Q · filed 2023-11-01
-$1.44M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30-$329.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02
-$701.00K
10-Q · filed 2023-08-02
-$1.12M
derived: sum of 3 quarters · filed 2024-02-29
-$1.46M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31-$372.00K
10-Q · filed 2023-05-03
-$795.00K
derived: sum of 2 quarters · filed 2024-02-29
-$1.13M
derived: sum of 3 quarters · filed 2024-02-29
-$1.63M
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31-$423.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
-$759.00K
derived: sum of 2 quarters · filed 2024-02-29
-$1.26M
derived: sum of 3 quarters · filed 2024-02-29
-$1.92M
10-K · filed 2024-02-29
2021-09-30-$336.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27
-$838.00K
derived: sum of 2 quarters · filed 2022-10-27
-$1.50M
10-Q · filed 2022-10-27
-$1.77M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30-$502.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
-$1.16M
10-Q · filed 2022-08-03
-$1.44M
derived: sum of 3 quarters · filed 2023-03-01
-$2.75M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31-$662.00K
10-Q · filed 2022-05-04
-$935.00K
derived: sum of 2 quarters · filed 2023-03-01
-$2.24M
derived: sum of 3 quarters · filed 2023-03-01
-$3.84M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31-$273.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
-$1.58M
derived: sum of 2 quarters · filed 2023-03-01
-$3.17M
derived: sum of 3 quarters · filed 2023-03-01
-$2.21M
10-K · filed 2023-03-01
2020-09-30-$1.31M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
-$2.90M
derived: sum of 2 quarters · filed 2021-11-03
-$1.94M
10-Q · filed 2021-11-03
-$674.00K
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$1.59M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
-$633.00K
10-Q · filed 2021-08-05
$634.00K
derived: sum of 3 quarters · filed 2022-03-01
$476.00K
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$961.00K
10-Q · filed 2021-04-29
$2.23M
derived: sum of 2 quarters · filed 2022-03-01
$2.07M
derived: sum of 3 quarters · filed 2022-03-01
$1.64M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$1.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$1.11M
derived: sum of 2 quarters · filed 2022-03-01
$683.00K
derived: sum of 3 quarters · filed 2022-03-01
$136.00K
10-K · filed 2022-03-01
2019-09-30-$158.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$584.00K
derived: sum of 2 quarters · filed 2020-11-05
-$1.13M
10-Q · filed 2020-11-05
-$1.38M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30-$426.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04
-$973.00K
10-Q · filed 2020-08-04
-$1.22M
derived: sum of 3 quarters · filed 2021-02-25
$931.00K
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31-$547.00K
10-Q · filed 2020-04-30
-$793.00K
derived: sum of 2 quarters · filed 2021-02-25
$1.36M
derived: sum of 3 quarters · filed 2021-02-25
$1.25M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31-$246.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$1.90M
derived: sum of 2 quarters · filed 2021-02-25
$1.80M
derived: sum of 3 quarters · filed 2021-02-25
$1.66M
10-K · filed 2021-02-25
2018-09-30$2.15M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
$2.04M
derived: sum of 2 quarters · filed 2019-11-05
$1.90M
10-Q · filed 2019-11-05
$1.52M
derived: sum of 4 quarters · filed 2020-02-25
2018-06-30-$106.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31
-$248.00K
10-Q · filed 2019-07-31
-$631.00K
derived: sum of 3 quarters · filed 2020-02-25
$1.31M
derived: sum of 4 quarters · filed 2020-02-25
2018-03-31-$142.00K
10-Q · filed 2019-05-01
-$525.00K
derived: sum of 2 quarters · filed 2020-02-25
$1.42M
derived: sum of 3 quarters · filed 2020-02-25
2017-12-31-$383.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$1.56M
derived: sum of 2 quarters · filed 2020-02-25
$1.22M
10-K · filed 2020-02-25
2017-09-30$1.94M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
$1.60M
10-Q · filed 2018-11-01
2017-06-30-$336.00K
10-Q · filed 2018-08-01
2016-12-31$884.00K
10-K · filed 2019-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Pulmatrix, Inc. (PULM)United States$0.006B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Ernexa Therapeutics Inc. (ERNA)United States$0.006B